A SLC16A1 mutation in an infant with ketoacidosis and neuroimaging assessment

Expanding the clinical spectrum of MCT1 deficiency

Sara Al-Khawaga, Jehan AlRayahi, Faiyaz Khan, Saras Saraswathi, Reem Hasnah, Basma Haris, Idris Mohammed, Essam Mohamed, Khalid Hussain

Research output: Contribution to journalArticle

Abstract

The solute carrier family 16 member 1 (SLC16A1) gene encodes for monocarboxylate transporter 1 (MCT1) that mediates the movement of monocarboxylates, such as lactate and pyruvate across cell membranes. Inactivating recessive homozygous or heterozygous mutations in the SLC16A1 gene were described in patients with recurrent ketoacidosis and hypoglycemia, a potentially lethal condition. In the brain where MCT1 is highly localized around axons and oligodendrocytes, glucose is the most crucial energy substrate while lactate is an alternative substrate. MCT1 mutation or reduced expression leads to neuronal loss due to axonal degeneration in an animal model. Herein, we describe a 28 months old female patient who presented with the first hypoglycemic attack associated with ketoacidosis starting at the age of 3 days old. Whole exome sequencing (WES) performed at 6 months of age revealed a c.218delG mutation in exon 3 in the SLC16A1 gene. The variant is expected to result in loss of normal MCT1 function. Our patient is amongst the youngest presenting with MCT1 deficiency. A detailed neuroimaging assessment performed at 18 months of age revealed a complex white and gray matter disease, with heterotopia. The threshold of blood glucose to circumvent neurological sequelae cannot be set because it is patient-specific, nevertheless, neurodevelopmental follow up is recommended in this patient. Further functional studies will be required to understand the role of the MCT1 in key tissues such as the central nervous system (CNS), liver, muscle and ketone body metabolism. Our case suggests possible neurological sequelae that could be associated with MCT1 deficiency, an observation that could facilitate the initiation of appropriate neurodevelopmental follow up in such patients.

Original languageEnglish
Article number299
JournalFrontiers in Pediatrics
Volume7
Issue numberJULY
DOIs
Publication statusPublished - 1 Jul 2019

Fingerprint

Ketosis
Neuroimaging
Mutation
Lactic Acid
Genes
Exome
Leukoencephalopathies
Ketone Bodies
Oligodendroglia
Pyruvic Acid
Hypoglycemia
Hypoglycemic Agents
Axons
Blood Glucose
Exons
Central Nervous System
Animal Models
Cell Membrane
Observation
Glucose

Keywords

  • Gray matter disease
  • Heterotopia
  • Hypoglycemia
  • Ketoacidosis
  • MCT1
  • SLC16A1
  • White matter disease

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

A SLC16A1 mutation in an infant with ketoacidosis and neuroimaging assessment : Expanding the clinical spectrum of MCT1 deficiency. / Al-Khawaga, Sara; AlRayahi, Jehan; Khan, Faiyaz; Saraswathi, Saras; Hasnah, Reem; Haris, Basma; Mohammed, Idris; Mohamed, Essam; Hussain, Khalid.

In: Frontiers in Pediatrics, Vol. 7, No. JULY, 299, 01.07.2019.

Research output: Contribution to journalArticle

Al-Khawaga, Sara ; AlRayahi, Jehan ; Khan, Faiyaz ; Saraswathi, Saras ; Hasnah, Reem ; Haris, Basma ; Mohammed, Idris ; Mohamed, Essam ; Hussain, Khalid. / A SLC16A1 mutation in an infant with ketoacidosis and neuroimaging assessment : Expanding the clinical spectrum of MCT1 deficiency. In: Frontiers in Pediatrics. 2019 ; Vol. 7, No. JULY.
@article{ce37f2a0d7ee437a9a1b148b26fe6322,
title = "A SLC16A1 mutation in an infant with ketoacidosis and neuroimaging assessment: Expanding the clinical spectrum of MCT1 deficiency",
abstract = "The solute carrier family 16 member 1 (SLC16A1) gene encodes for monocarboxylate transporter 1 (MCT1) that mediates the movement of monocarboxylates, such as lactate and pyruvate across cell membranes. Inactivating recessive homozygous or heterozygous mutations in the SLC16A1 gene were described in patients with recurrent ketoacidosis and hypoglycemia, a potentially lethal condition. In the brain where MCT1 is highly localized around axons and oligodendrocytes, glucose is the most crucial energy substrate while lactate is an alternative substrate. MCT1 mutation or reduced expression leads to neuronal loss due to axonal degeneration in an animal model. Herein, we describe a 28 months old female patient who presented with the first hypoglycemic attack associated with ketoacidosis starting at the age of 3 days old. Whole exome sequencing (WES) performed at 6 months of age revealed a c.218delG mutation in exon 3 in the SLC16A1 gene. The variant is expected to result in loss of normal MCT1 function. Our patient is amongst the youngest presenting with MCT1 deficiency. A detailed neuroimaging assessment performed at 18 months of age revealed a complex white and gray matter disease, with heterotopia. The threshold of blood glucose to circumvent neurological sequelae cannot be set because it is patient-specific, nevertheless, neurodevelopmental follow up is recommended in this patient. Further functional studies will be required to understand the role of the MCT1 in key tissues such as the central nervous system (CNS), liver, muscle and ketone body metabolism. Our case suggests possible neurological sequelae that could be associated with MCT1 deficiency, an observation that could facilitate the initiation of appropriate neurodevelopmental follow up in such patients.",
keywords = "Gray matter disease, Heterotopia, Hypoglycemia, Ketoacidosis, MCT1, SLC16A1, White matter disease",
author = "Sara Al-Khawaga and Jehan AlRayahi and Faiyaz Khan and Saras Saraswathi and Reem Hasnah and Basma Haris and Idris Mohammed and Essam Mohamed and Khalid Hussain",
year = "2019",
month = "7",
day = "1",
doi = "10.3389/fped.2019.00299",
language = "English",
volume = "7",
journal = "Frontiers in Pediatrics",
issn = "2296-2360",
publisher = "Frontiers Media S. A.",
number = "JULY",

}

TY - JOUR

T1 - A SLC16A1 mutation in an infant with ketoacidosis and neuroimaging assessment

T2 - Expanding the clinical spectrum of MCT1 deficiency

AU - Al-Khawaga, Sara

AU - AlRayahi, Jehan

AU - Khan, Faiyaz

AU - Saraswathi, Saras

AU - Hasnah, Reem

AU - Haris, Basma

AU - Mohammed, Idris

AU - Mohamed, Essam

AU - Hussain, Khalid

PY - 2019/7/1

Y1 - 2019/7/1

N2 - The solute carrier family 16 member 1 (SLC16A1) gene encodes for monocarboxylate transporter 1 (MCT1) that mediates the movement of monocarboxylates, such as lactate and pyruvate across cell membranes. Inactivating recessive homozygous or heterozygous mutations in the SLC16A1 gene were described in patients with recurrent ketoacidosis and hypoglycemia, a potentially lethal condition. In the brain where MCT1 is highly localized around axons and oligodendrocytes, glucose is the most crucial energy substrate while lactate is an alternative substrate. MCT1 mutation or reduced expression leads to neuronal loss due to axonal degeneration in an animal model. Herein, we describe a 28 months old female patient who presented with the first hypoglycemic attack associated with ketoacidosis starting at the age of 3 days old. Whole exome sequencing (WES) performed at 6 months of age revealed a c.218delG mutation in exon 3 in the SLC16A1 gene. The variant is expected to result in loss of normal MCT1 function. Our patient is amongst the youngest presenting with MCT1 deficiency. A detailed neuroimaging assessment performed at 18 months of age revealed a complex white and gray matter disease, with heterotopia. The threshold of blood glucose to circumvent neurological sequelae cannot be set because it is patient-specific, nevertheless, neurodevelopmental follow up is recommended in this patient. Further functional studies will be required to understand the role of the MCT1 in key tissues such as the central nervous system (CNS), liver, muscle and ketone body metabolism. Our case suggests possible neurological sequelae that could be associated with MCT1 deficiency, an observation that could facilitate the initiation of appropriate neurodevelopmental follow up in such patients.

AB - The solute carrier family 16 member 1 (SLC16A1) gene encodes for monocarboxylate transporter 1 (MCT1) that mediates the movement of monocarboxylates, such as lactate and pyruvate across cell membranes. Inactivating recessive homozygous or heterozygous mutations in the SLC16A1 gene were described in patients with recurrent ketoacidosis and hypoglycemia, a potentially lethal condition. In the brain where MCT1 is highly localized around axons and oligodendrocytes, glucose is the most crucial energy substrate while lactate is an alternative substrate. MCT1 mutation or reduced expression leads to neuronal loss due to axonal degeneration in an animal model. Herein, we describe a 28 months old female patient who presented with the first hypoglycemic attack associated with ketoacidosis starting at the age of 3 days old. Whole exome sequencing (WES) performed at 6 months of age revealed a c.218delG mutation in exon 3 in the SLC16A1 gene. The variant is expected to result in loss of normal MCT1 function. Our patient is amongst the youngest presenting with MCT1 deficiency. A detailed neuroimaging assessment performed at 18 months of age revealed a complex white and gray matter disease, with heterotopia. The threshold of blood glucose to circumvent neurological sequelae cannot be set because it is patient-specific, nevertheless, neurodevelopmental follow up is recommended in this patient. Further functional studies will be required to understand the role of the MCT1 in key tissues such as the central nervous system (CNS), liver, muscle and ketone body metabolism. Our case suggests possible neurological sequelae that could be associated with MCT1 deficiency, an observation that could facilitate the initiation of appropriate neurodevelopmental follow up in such patients.

KW - Gray matter disease

KW - Heterotopia

KW - Hypoglycemia

KW - Ketoacidosis

KW - MCT1

KW - SLC16A1

KW - White matter disease

UR - http://www.scopus.com/inward/record.url?scp=85069786347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069786347&partnerID=8YFLogxK

U2 - 10.3389/fped.2019.00299

DO - 10.3389/fped.2019.00299

M3 - Article

VL - 7

JO - Frontiers in Pediatrics

JF - Frontiers in Pediatrics

SN - 2296-2360

IS - JULY

M1 - 299

ER -